Sharon Susan Paul

Dr. Sharon Susan Paul

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2026 in Clinical Bioenergetics
Verified
Journal Article
Open access
PDF file
ELEunseuk Lee
Eunseuk Lee
FBFranklyn Vega Batista
Franklyn Vega Batista
SPSharon Susan Paul
Sharon Susan Paul
ASAnshu Sutihar
Anshu Sutihar
DADana Al-Assi
Dana Al-Assi
Myeloid malignancies exhibit profound metabolic dependence on mitochondrial oxidative phosphorylation (OXPHOS) for survival and proliferation. Antileukemic therapies such as Venetoclax combined with Azacitidine or cytarabine induce rapid mitochondrial collapse, disrupting electron transport, NADH oxidation, and ATP synthesis, followed by a selective rebound of fatty-acid oxidation (FAO) and redox-buffering programs that sustain minimal residual disease. This review integrates current mechanistic and clinical insights into therapy-induced mitochondrial suppression, delineates the regulatory circuitry that enables metabolic recovery, and frames these events as a reversible model of clinical energy deficiency. By linking mitochondrial stress signaling, lipid oxidation, and adaptive redox metabolism, we outline how bioenergetic reprogramming drives therapeutic resistance and propose interventions that target this adaptive axis in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and related myeloid neoplasms.

Verified
Journal Article
Open access
PDF file
SSShreya Shambhavi
Shreya Shambhavi
AJAksa Alina Joy
Aksa Alina Joy
HSHarmanjeet Singh
Harmanjeet Singh
TATerence Amonica
Terence Amonica
AGAstha Grover
Astha Grover
TPTiffany Pompa
Tiffany Pompa
Relapsed/refractory multiple myeloma is marked by frequent triple-class refractoriness and poor survival, whereas bispecific antibodies targeting BCMA, GPRC5D, or FcRH5 show meaningful activity even in heavily pretreated and post-BCMA disease. This meta-analysis evaluates and compares the efficacy and safety of these agents in RRMM using direct and indirect evidence. We manually searched seven databases and identified 44 studies for quantitative analysis. Forest plots were created using R 4.1.1 software. Compared to Standard of care (SOC), the odds of Objective response rate (ORR) were higher with Talquetamab, Teclistamab, Elranatamab, and Linvoseltamab (5.73, 4.86, 3.84, and 2.63). PFS improved with Teclistamab (HR 0.50, 95% CI 0.36–0.55), Talquetamab (0.50, 0.36–0.55), Elranatamab (0.45, 0.36–0.55), and Linvoseltamab (0.23, 0.17–0.31). Linvoseltamab and Elranatamab showed numerically longer OS relative to SOC (HR 0.41, 0.24–0.70 and HR 0.58, 0.43–0.78, respectively), but numerically shorter OS with Teclistamab (HR 1.82, 1.37–2.42) and Talquetamab (HR 1.75, 1.20–2.57). In pooled single-arm data, Talquetamab had the highest ORR (72%) and CRS rate (68%); Teclistamab showed an ORR of 61% with a CRS rate of 61% and Linvoseltamab showed an ORR of 60% with a CRS rate of 51%. Cevostamab and Elranatamab had ORRs of 49% and 56% with CRS rates of 61% and 52%, respectively. In RRMM, all bispecific antibodies showed superior ORR along with improved PFS compared to SOC. Linvoseltamab and Elranatamab showed numerically longer OS relative to SOC, whereas Talquetamab and Teclistamab showed numerically shorter OS versus SOC, within the constraints of adjusted cross-trial comparisons.

1 August 2026 in Journal of Clinical Medicine Research
Verified
Journal Article
Open access
PDF file
JRJackson Rajendran
Jackson Rajendran
SSShubhangi Sharma
Shubhangi Sharma
FBFranklyn Vega Batista
Franklyn Vega Batista
ASAnshu Sutihar
Anshu Sutihar
SPSharon Susan Paul
Sharon Susan Paul
JIJose Iglesias
Jose Iglesias
Background: Acute kidney injury (AKI) is common in cardiogenic shock and is associated with poor outcomes. Whether routinely available inflammatory indices add useful information for AKI risk stratification in this population remains unclear. Methods: We performed a retrospective multicenter cohort study using the eICU Collaborative Research Database. Adult intensive care unit (ICU) patients with cardiogenic shock were included if laboratory components required to calculate inflammatory indices were available. All indices were derived from a single set of laboratory values obtained on ICU admission rather than from serial measurements. AKI was defined using creatinine-based Kidney Disease: Improving Global Outcomes criteria and renal replacement therapy status. We evaluated neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, monocyte to lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, aggregate index of systemic inflammation, and neutrophil percentage to albumin ratio. Missing covariate data were handled using multiple imputation. Multivariable logistic regression, false discovery rate correction, elastic-net analysis, calibration, and decision-curve analysis were used to assess associations and incremental discrimination. Results: The final cohort included 419 patients, of whom 273 (65.1%) developed AKI. Baseline creatinine was the strongest variable associated with AKI in the primary multivariable model. Chronic kidney disease was associated with AKI when creatinine and blood urea nitrogen were excluded. Inflammatory indices were not independently associated with AKI after multivariable adjustment and false discovery rate correction. The base clinical model had modest discrimination, which improved after adding renal laboratory variables. Adding inflammatory indices provided little to no meaningful incremental discrimination, and inflammatory indices were not consistently retained in elastic-net models. Conclusion: In this multicenter ICU cohort of patients with cardiogenic shock, AKI was associated mainly with baseline renal dysfunction and illness severity. Routine inflammatory indices did not provide meaningful incremental discrimination beyond established clinical and renal variables for AKI during ICU hospitalization. These findings apply to blood count-derived indices and do not exclude a contribution of inflammation to AKI in cardiogenic shock.

14 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SSShreya Shambhavi
Shreya Shambhavi
HSHarmanjeet Singh
Harmanjeet Singh
TATerence Amonica
Terence Amonica
AGAstha Grover
Astha Grover
TSTanya Singh
Tanya Singh
TPTiffany Pompa
Tiffany Pompa
Background: Relapsed/refractory multiple myeloma is marked by frequent triple-class refractoriness and poor survival, whereas bispecific antibodies targeting BCMA, GPRC5D, or FcRH5 show meaningful activity even in heavily pretreated and post-BCMA disease.This meta-analysis evaluates and compares the efficacy and safety of these agents in RRMM using direct and indirect evidence. Methods: We manually searched 7 databases and identified 44 studies for quantitative analysis. Forest plots were created using R 4.1.x software. Results: Versus SOC, odds of ORR were higher with Talquetamab, Teclistamab, Elranatamab, and Linvoseltamab (5.73, 4.86, 3.84, 2.63). PFS improved with Teclistamab (HR 0.50, 95% CI 0.36–0.55), Talquetamab (0.50, 0.36–0.55), Elranatamab (0.45, 0.36–0.55), and Linvoseltamab (0.23, 0.17–0.31). Linoseltamab and Elranatamab showed numerically longer OS relative to SOC ( HR 0.41, 0.24–0.70) and (HR 0.58, 0.43–0.78), but numerically shorter OS with Teclistamab (HR 1.82, 1.37–2.42) and Talquetamab (HR 1.75, 1.20–2.57). In pooled single‑arm data, Talquetamab had the highest ORR (72%) and CRS (68%); Teclistamab showed ORR of 61% with CRS 61% and Linvoseltamab showed ORR of 60% with CRS 51%. Cevostamab and Elranatamab had ORR 49% and 56% with CRS 61% and 52%, respectively. Conclusion: In RRMM, all bispecific antibodies showed superior ORR along with improved PFS as compared to SOC. Linoseltamab and Elranatamab showed numerically longer OS relative to SOC, whereas Talquetamab and Teclistamab showed numerically shorter OS versus SOC, within the constraints of adjusted cross-trial comparisons.